Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 May 2017
At a glance
- Drugs Ustekinumab (Primary) ; Sirolimus; Tacrolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 28 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 25 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.